supported by the National Natural Science Foundation of China(82225021);the National Key R&D Program of China(2022YFC2303403,2021YFA1300803,2021YFA1301404).
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is continuously evolving since 2019.Some monoclonal antibodies(mAbs)have been developed and widely used,such as etesevimab(CB6)developed by Eli-Lilly/Junshi.H...
As new COVID-19 strains surface and proliferate over the world,the pandemic is still evolving[1].The FLiRT variants are one such family of variants that have recently drawn notice.They are a family of Omicron sub-vari...